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ABSTRACT

Article Type:
Review

Genetic variants of apolipoprotein L1 (APOL1) have been recognized as a risk factor for
kidney disease in people of African ancestry. APOL1 mediate renal damage in podocytes
through necrosis, apoptosis and pyroptosis processes. APOL1 gene contains G1 and G2
alleles that mediate in increasing risk of renal disorders in African Americans. People
who carry APOL1 risk alleles have a three to four-fold increase risk for non-diabetic renal
disease (NDRD), Idiopathic focal segmental glomerulosclerosis (FSGS) and HIV-associated
nephropathy (HIVAN). Therefore, identifying genetic factors involved in the pathogenesis of
renal disorders, including APOL1 risk variants, may help to improve our understanding of
kidney problems.
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Implication for health policy/practice/research/medical education:

Apolipoprotein L1 risk variants are more common in some races. Apolipoprotein L1 risk variants are involved in various CKDs.
The APOL1 involves necrosis, apoptosis and pyroptosis processes in various types of kidney cells including podocytes.
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an overview. J Renal Inj Prev. 2019; 8(4): 311-315. DOI: 10.15171/jrip.2019.57.

Introduction
Chronic kidney disease (CKD) is one of the major public
health problems, including renal replacement therapy.
Advanced CKD is associated with adverse outcomes and
disability (1, 2). CKD is categorized based on its etiology,
kidney function (GFR category), and markers of kidney
damage (albuminuria category) (3). Several studies
identified some genetic factors that contribute to the
progression of CKD in non-diabetic African-American
race (4). The prevalence of end-stage renal disease (ESRD)
is five times greater in people with African ancestors than
the Caucasians. This led to the identification of some
genetic factors that are contributing to renal disease in
these populations. Apolipoprotein L1 (APOL1) protein
that encoded by the human APOL1 gene is one of the
risk factors for non-diabetic renal disease (NDRD) in the
African ancestors’ population (5). Secretory lipoprotein,

APOL1 circulates in HDL3 complexes and is expressed in
various tissues (6). Genetic studies show that the two G1 and
G2 alleles of the APOL1 gene are significantly associated
with the risk of various types kidney diseases including
NDRD, Idiopathic focal segmental glomerulosclerosis
(FSGS) and HIV-associated nephropathy (HIVAN) in
African Americans (7). The APOL1 and MYH9 were
identified as independent nephropathy susceptibility loci
in African-American with FSGS and other CKDs (8-10).
This review discusses the current knowledge regarding
pathophysiological and clinical aspects of APOL1,
including its role in renal disease.
Materials and Methods
Articles related to this topic were searched in Web of
Science, PubMed, Embase, Scopus and the directory of
open access journals (DOAJ), using specific combination
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of keywords. The keywords used are apolipoprotein
L1, nephropathy, CKD, ESRD and APOL1-related
nephropathy.
APOL1 genetic variants
The human APOL family of proteins is mainly involved
in lipid transport and metabolism. APOL1 risk alleles
exhibit increased risk for hyperlipidemia, obesity and
atherosclerosis (11). In addition, APOL family is involved
in innate host immunity, apoptosis and autophagy due
to their structural similarities with bacterial colicins
and other Bcl-2 family of proteins (12). The human
APOL family consists of six genes that are located on
chromosome 22q12.3. APOL1 is produced by hepatocytes
and is part of the circulating HDL complex. It expressed
in various cell types including macrophages, kidney, brain
and pancreas (4,13,14). APOL1 gene is associated with
some diseases, including schizophrenia, prostate cancer,
liver cancer, and breast cancer (15). The last exon of the
APOL1 gene harbors two alleles (G1 and G2). G1 includes
two mutations (rs73885319 and rs60910145) that result
in amino acid substitutions at positions 342 (serine 342
glycine) and 384 (isoleucine 384 methionine). G2 allele
(rs71785313) is a 6-base pair in-frame deletion that
removes asparagine 388 and tyrosine 389 amino acids
(16). G1 and G2 alleles are located 12 base pair apart
and are in perfect negative linkage disequilibrium (17).
In some populations, G1 allele occurs more frequently
(20%-22%) than the G2 allele (13%-15%). About 10%15% African-Americans have two APOL1 risk alleles (16).
The frequency of G1 and G2 varies across Africa. The
G1 is more prevalent in west Africa, while the G2 allele
is consistently distributed through Africa. Based on the
presence of G1 and G2 alleles in Africa, various genotype
combinations of risk alleles such as homozygous (G1G1
or G2G2), heterozygous (G1G0 or G2G0) and compound
heterozygous (G1G2) are possible (Figure 1).
The role of APOL1 genetic variants in kidney disease
The FSGS and type 2 diabetes-related CKDs are the
prevalent renal disorders in African Americans. Over the
past decade, APOL1 mutations have been identified in
African individuals and attributed as one of the important
risk factors for CKD in this population (8,13,17). The
APOL1-associated nephropathy comprises NDRD that
include lupus nephritis, hypertensive nephrosclerosis,
primary FSGS and HIVAN (18). African Americans
carrying APOL1 genotypes have higher rates of albuminuria
and decreased renal function with faster progression
to ESRD than Caucasians (19,20). Immunohistological
studies revealed the presence of APOL1 in arteriolar
endothelium and epithelium of proximal tubule in normal
kidneys, FSGS and HIVAN (21). Surprisingly, APOL1
was detected in the media of medium size arteries and
arterioles of both FSGS and HIVAN kidneys but not in
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Figure 1. The APOL1 gene risk alleles. The figure depicts the genomic
organization of the APOL1 gene on chromosome 22q12.3. Risk alleles
are involved in modulation of inflammation by autophagy and altered lipid
metabolism. The risk alleles offer protection against trypanosomiasis.
Increase risk of cardiovascular disease and renal failure. Note; This
illustration is based on the information obtained from existing literature.

normal kidneys (21). Evaluation of associations of APOL1
genotype and urine biomarkers of glomerular and tubular
injury in HIV-infected African women demonstrated that
the renal damage associated with APOL1 is more likely
to be associated with glomerular injury (22). Therefore,
the identification of renal APOL1 localization may help
elucidate the mechanisms involved in the development
of nephropathy. Various histopathologic findings have
been documented in relation to APOL1-associated
nephropathy in human and animal models, including
solidified glomerulosclerosis, sickle cell nephropathy,
severe lupus nephritis and FSGS (23). Analysis of renal
biopsies of hypertension-attributed CKD in African
Americans without nephrotic syndrome showed the
presence of obsolescent glomerulosclerosis along with
APOL1 risk alleles (24). Furthermore, APOL1 gene alleles
were also found in African Americans receiving kidney
transplant and these APOL1 alleles were not related to
the increased risk of post-transplant allograft dysfunction
(25).
In CKD, kidney lesions caused by an array of etiological
factors lead to the loss of renal parenchyma and impaired
kidney function. Most studies have shown that individuals
carrying homozygous (G1G1 or G2G2), heterozygous
(G1G0 or G2G0) and compound heterozygous (G1G2)
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forms of APOL1 alleles are susceptible to CKD. Meanwhile,
individuals with G1G1 homozygotes showed higher risk
for CKD and albuminuria (26). African American patients
with CKD who are carriers of two APOL1 risk alleles
exhibit faster progression to ESRD compared to the ones
who are carriers of zero or one APOL1 risk allele (27).
Despite a strong association between the presence of
APOL1 risk variants and the risk of developing nephropathy,
its association with diabetic glomerulosclerosis is unlikely
(9,10,18). The APOL1 gene is restricted to humans
and several primates. The pathogenic mechanisms of
APOL1 risk variants in renal lesions are unclear (24).
However, different mechanisms have been considered
in relation to APOL1 renal risk variants on renal cells
including podocytes and their role in the development of
glomerulopathies in vivo.

greatly increase the expression of APOL1 nonrisk (NR)
in a variety of cells in vitro. The APOL1 also secreted
proteins that are found in circulation and reach lysosomal
compartments via endosomal trafficking pathway (35).
Silencing of APOL1 enhanced miR193a expression which
leads to dedifferentiation of differentiated podocytes. The
APOL1 function is dependent on the intact interaction
of APOL1-miR193a axis (36). The miR193a negatively
regulates Wilms’ tumor 1 (WT1), a major transcriptome
of podocyte markers like nephrin and podocalyxin. In
addition, APOL1 induced podocin, podocalyxin and WT1
in human embryonic kidney cells (21,28,37). Lentivirusmediated of APOL1 variants transduction to human
podocyte indicated that the APOL1 risk variants have the
potential to induce podocyte injury through enhanced
lysosomal membrane permeability (38).

Mechanisms of cell damage in APOL1-related nephropathy
Cellular expression of APOL1 renal risk variants (RRVs)
is linked with cell death related processes (apoptosis,
necrosis, pyroptosis and autophagy) in various types
of cells containing podocytes. This APOL1-mediated
cell toxicity leads to swelling of lysosomes, potassium
depletion and mitochondrial dysfunction, autophagy,
protein kinase receptor activation, ubiquitin D activation,
and endoplasmic reticulum stress. However, these effects
were found only in cells containing APOL1 RRVs (28).
Experimental evidence suggests that the non-risk allele of
the APOL1 gene (G0) was shown to provoke autophagic
cell death in human colorectal cancer cell lines (29).
Whereas the APOL1 G1 and G2 alleles significantly
increased the toxicity in HEK-293 cells and podocytes
compared to G0 allele (30). However, it still remains
unclear whether the increased toxicity occurs through the
same or separate mechanism (31).
The major mechanisms that contribute to APOL1 toxicity
include lysosome stimulation, apoptosis, autophagy and/
or endocytosis. Recent evidence shows that APOL1 risk
alleles interact with genetic or environmental parameters
that induce apoptosis in renal cells. The APOL family
holds a Bcl-2 homology domain3 within the pore-forming
domain; and may act as apoptotic activators and cause
autophagic cell death in specific situations (32). APOL1 G1
also induced cytotoxicity either by K-current or activation
of the stress-activated protein kinases (SAPK) pathway.
The activated SAPKs cause toxicity and cell death through
downstream effectors that control the flow of Na, Cl, and
H2O which leads to cytoplasmic swelling (33). APOL1
proteins are involved in the formation of selective pores of
cation K in the plasma membrane leading to an increase
in intracellular K efflux. The efflux of intracellular cation
K subsequently activates p38, c-JUN N-terminal kinase,
extracellular signal-regulated kinase and mitogenactivated protein kinase pathways (34).
Experimental data demonstrated that cytokines

Conclusion
APOL1-RRV emerged in sub-Saharan Africa as a
protection against sleeping disease caused by Trypanosoma
brucei rhodesiense but increased the risk of CKD. This
review provides a summary of existing evidence on APOL1
risk variants, as one of the players that cause kidney
disease. Variety of environmental and interactive genetic
variations influence the risk of developing nephropathy.
Screening in the patients carrying APOL1 risk variants
may lead to new preventive and therapeutic measures.
Alternatively, targeting other mutable genes may direct
toward preventive modalities to reduce the development
of NDRD in various populations with two types of APOL1
risk variations. Therefore, further research on APOL1
could be an important step towards a better understanding
of the problems of NDRD in these populations.
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